Handelsavisen
prelaunch
Companies Healthcare NORDH.OL
NO
NORDH.OL Oslo Børs Advanced Medical Equipment & Technology

Nordhealth AS

kr23,60
Open in Charts → Attach watcher ⌖
NOK
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
1,0B NOK
P/E
EV / Rev
Div yield
0,00 %
Op margin
-24,5 %
ROE
-20,6 %
Net margin
-24,9 %
Debt / equity
0,00
Beta
52w range
Volume
6,7k
Day range
kr28,00–kr29,00
Prev close
kr28,80
Open
kr29,00
Next earnings
2026-08-18
Ex-dividend
TR 1Y
About

Nordhealth AS is a healthcare equipment company that provides medical technology solutions, primarily generating revenue through the sale and service of diagnostic and therapeutic equipment.

Business. Nordhealth AS (NORDH.OL) is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is headquartered in Norway and is listed on the Oslo Børs. Specific details regarding its operating segments and geographic revenue mix are not disclosed.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
ActivityHealthcare Equipment
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target33,00

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
33,00
Consensus of sell-side coverage.
Upcoming events
  • EarningsH1 2026 earnings (expected)2026-08-18 · estimated
  • EarningsQ3 2026 earnings (expected)2026-11-10 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
not yet wired
Profitability
-20,6 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning NORDH.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to NORDH.OL. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsH1 2026 earnings (expected)2026-08-18 · estimated
    • EarningsQ3 2026 earnings (expected)2026-11-10 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Nordhealth AS (NORDH.OL) is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is headquartered in Norway and is listed on the Oslo Børs. Specific details regarding its operating segments and geographic revenue mix are not disclosed.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryAdvanced Medical Equipment & Technology
    ActivityHealthcare Equipment
    AI synthesis
    GENERATED

    Nordhealth AS has a strong liquidity position with a current ratio of 2.21, indicating the company can cover its short-term liabilities with its current assets. The company holds EUR 14.7 million in cash and equivalents, which is a significant portion of its total assets of EUR 71.5 million. However, the company's free cash flow is negative at EUR -6.5 million, driven by capital expenditures of EUR -5.1 million.

    Profitability metrics show a challenging financial position for Nordhealth AS. The company reported a net loss of EUR -12.7 million and an operating loss of EUR -12.5 million in the latest period. Return on equity is negative at -20.6%, and return on assets is also negative at -17.7%. These figures are below the industry median for profitability metrics, indicating that Nordhealth AS is underperforming relative to its peers in the Advanced Medical Equipment & Technology industry.

    Geographically, Nordhealth AS is primarily focused on the Nordic region, with a significant portion of its EUR 50.8 million in revenue derived from Norway. The company has limited international exposure, which could pose a concentration risk if the Norwegian market experiences economic downturns or regulatory changes.

    Looking ahead, Nordhealth AS is expected to maintain a stable revenue trajectory, with no significant growth or decline projected in the next fiscal year. The company's capital expenditures are expected to remain at current levels, and there are no immediate signs of aggressive expansion or contraction in the business.

    The risk assessment for Nordhealth AS indicates a low level of liquidity risk, supported by its strong cash position and absence of long-term debt. However, the company's negative operating and net income raise concerns about its ability to sustain operations without external financing. The risk of dilution is also low, as there are no immediate filing-based flags indicating potential share dilution.

    Recent events and filings for Nordhealth AS show a consistent financial position with no major changes in the company's capital structure or operations. The company has not issued new shares or taken on additional debt in the latest reporting period. Analysts have a strong buy rating for the stock, with a mean price target of EUR 33.00, suggesting confidence in the company's long-term prospects despite its current financial challenges.

    Key takeaways
    • Nordhealth AS has a strong liquidity position with a current ratio of 2.21 and EUR 14.7 million in cash and equivalents.
    • The company is currently unprofitable, with a net loss of EUR -12.7 million and a return on equity of -20.6%.
    • Nordhealth AS is heavily concentrated in the Nordic region, particularly Norway, which could pose a concentration risk.
    • Analysts have a strong buy rating for the stock, with a mean price target of EUR 33.00.
    • The company has no immediate liquidity or dilution risks, but its negative operating and net income raise concerns about long-term sustainability.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    kr23,60
    Market cap
    kr1.15B
    Enterprise value
    kr1.13B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    1578.5x
    P / B
    18.7x
    P / Tangible book
    18.7x
    Tangible book
    kr61.6M
    Net cash
    kr14.7M
    Current ratio
    2.2
    Debt / equity
    0.0
    ROA
    -17.7%
    ROE
    -20.6%
    Cash conversion
    -6.0%
    CapEx / revenue
    -10.0%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,03
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-10 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-0,03
    Revenueno estimateno estimate57,2M EUR
    Operating incomeno estimateno estimate-8,7M EUR
    Full-year consensus mean (period as reported by source) · consensus in EUR. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy1
    Buy0
    Hold0
    Sell0
    Strong sell0
    12-month price targetkr33,00 · Median kr33,00
    Low kr33,00High kr33,00
    Operating income · consensus-8,7M EUR
    EPS surprise
    −6 140,0 %
    reported vs consensus · miss
    Revenue surprise
    +940,2 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Lowkr33,00
    Meankr33,00
    Mediankr33,00
    Highkr33,00
    Spotkr23,60
    +39.8 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-24,5 %Below median
    Net Margin-24,9 %Below median
    ROE-20,6 %Below median
    Capex / Rev-10,0 %Bottom quartile
    D/E0,00Above median
    Cash Conv-0,06Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • Nordhealth AS Market data — financials · 2026-05-28
    • Nordhealth AS Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Leadership

    • Charles William MacbainCEO

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    NORDH.OLCanonical
    Oslo Børs · NOK

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    • Return on equity (FY 2024-12-31): 0.3%Derived (calculated)
    • Return on assets (FY 2024-12-31): 0.3%Derived (calculated)
    • Current ratio (FY 2024-12-31): 9.40xDerived (calculated)
    • Debt-to-equity (FY 2024-12-31): 0.00xDerived (calculated)
    • Total assets (annual): NOK 3.16BBRREG filing
    • Total equity & liabilities (annual): NOK 3.16BBRREG filing
    • Net income (annual): NOK 8.37MBRREG filing
    • Non current liabilities (annual): NOK 0BRREG filing
    • Current liabilities (annual): NOK 3.19MBRREG filing
    • Operating income (annual): NOK -6.14MBRREG filing
    • Total liabilities (annual): NOK 3.19MBRREG filing
    • Shareholders' equity (annual): NOK 3.16BBRREG filing
    • Non current assets (annual): NOK 3.13BBRREG filing
    • Total operating expenses (annual): NOK 6.14MBRREG filing
    • Pre-tax income (annual): NOK 8.37MBRREG filing
    • Current assets (annual): NOK 29.99MBRREG filing
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-11-10EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-08-18EVENTUpcomingH1 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-05-21 05:23 UTCFILINGRegulatory filing →
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage